Viridian Therapeutics/$VRDN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Ticker
- $VRDN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 252
- Headquarters
- Waltham, United States
- Website
- www.viridiantherapeutics.com
VRDN Metrics
BasicAdvanced
$2.9B
-
-$3.46
0.96
-
Price and volume
Market cap
$2.9B
Beta
0.96
52-week high
$34.29
52-week low
$13.18
Average daily volume
2.1M
Financial strength
Current ratio
16.949
Quick ratio
16.562
Long term debt to equity
0.369
Total debt to equity
0.37
Interest coverage (TTM)
-25.95%
Profitability
EBITDA (TTM)
-404.731
Gross margin (TTM)
-356.47%
Net profit margin (TTM)
-544.06%
Operating margin (TTM)
-569.68%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-30.16%
Return on equity (TTM)
-65.74%
Valuation
Price to revenue (TTM)
34.361
Price to book
5.08
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
-7.295
Free cash flow yield (TTM)
-13.71%
Free cash flow per share (TTM)
-3.468
Growth
Revenue change (TTM)
23,220.33%
Earnings per share change (TTM)
-2.96%
3-year revenue growth (CAGR)
264.40%
3-year earnings per share growth (CAGR)
-11.26%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Analyst projections of the future price of Viridian Therapeutics stock.
Bulls say / Bears say
Lumvoa is now FDA-approved on the strength of trials in active and chronic TED, with a shorter five-infusion course than Tepezza’s eight. In the active-disease trial, 70% of patients had a proptosis response versus 5% on placebo, and the approval gives Viridian a commercial product rather than a development-stage story alone. (Reuters, American Academy of Ophthalmology)
Early launch indicators point to meaningful physician interest: Viridian had engaged 95% of its 2,000 core prescribers by the end of July, and said initial patient forms showed broad demand. Payer coverage efforts were also reported to be progressing. (Viridian Therapeutics)
Elegrobart has positive phase 3 results in both active and chronic TED, and the active-disease trial met its primary endpoint with both monthly and every-eight-week dosing. If approved, its self-administered subcutaneous format could offer a lower-burden option; Viridian was targeting a BLA filing in Q1 2027. (Ophthalmology Management, Viridian Therapeutics)
Lumvoa must win share from Amgen’s established Tepezza franchise, and Amgen is developing a subcutaneous Tepezza that could narrow any convenience gap. That may limit Viridian’s ability to turn its shorter infusion regimen into lasting differentiation. (BioSpace)
Commercial uptake may take time to translate into sales: Viridian’s September update described slow prior-authorisation processes and a market that remains only partly developed. Strong physician engagement is encouraging, but it does not yet show that patients are progressing quickly through payer approval and treatment. (Investing.com)
Hearing impairment is a material safety concern for Lumvoa: in its clinical trials, it was reported in 17% of treated participants versus 6% on placebo, and the label calls for hearing checks before, during and after treatment. This could deter some patients or prescribers, even though hearing risks are also associated with the drug class. (MedCity News)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
Upcoming events
No upcoming events
VRDN News
AllArticlesVideos
Funds containing VRDN
Fund name | Fund size | $VRDN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.26% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.26% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.26% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.